Key Takeaway: Precision BioSciences has submitted its first clinical trial applications to initiate a Phase 1 trial for PBGENE-HBV, a novel gene editing treatment for chronic hepatitis B. This drug modality aims to target the root cause of the disease by eliminating cccDNA and inactivating integrated HBV. The submission marks a significant step in advancing this innovative approach.
Price reaction · baseline $9.05 (2024-09-27 close) · hit pre-market · 1 other DTIL headline(s) in the window, move may be shared
day 0 close
-1%
Market Sentiment Analysis
POSITIVE FACTORS
First clinical trial applications submitted for PBGENE-HBV.
Innovative gene editing approach targeting root cause of chronic hepatitis B.
Potential to eliminate cccDNA and inactivate integrated HBV.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
– PBGENE-HBV is the only drug modality designed to target the root cause of disease by eliminating cccDNA and inactivating integrated HBV – Clinical trial applications submitted for the first gene editing approach for chronic hepatitis B – Final clinical candidate safety data and plans for the
Frequently Asked Questions
What is PBGENE-HBV?
PBGENE-HBV is a gene editing drug designed to treat chronic hepatitis B by targeting cccDNA.
What phase trial is Precision BioSciences initiating?
Precision BioSciences is initiating a Phase 1 trial for PBGENE-HBV.
What does PBGENE-HBV aim to eliminate?
PBGENE-HBV aims to eliminate cccDNA and inactivate integrated HBV.
Why is PBGENE-HBV significant?
It is the first gene editing approach targeting the root cause of chronic hepatitis B.